CRB-4001

CRB-4001

Preclinical Phase 1 Phase 2 Phase 3 Launch
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
Launch Phase not started

Scheduled to Enter Phase 1 in 2019, NIH Committed to Funding Phase 2 Study.

On September 20, 2018, Corbus Pharmaceuticals licensed the exclusive worldwide rights to develop, manufacture and market drug candidates from more than 600 novel compounds targeting the endocannabinoid system from Jenrin Discovery, LLC. The pipeline includes CRB-4001, a 2nd generation, peripherally-restricted, CB1 inverse agonist.

CRB-4001 was developed in collaboration with and financial support from the National Institutes of Health (NIH). CRB-4001 was specifically designed to eliminate blood-brain barrier penetration and brain CB1 receptor occupancy that mediate the neuropsychiatric issues associated with first-generation CB1 inverse agonists such as rimonabant.

Scientific Director of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) George Kunos, MD, PhD, who concomitantly joined the Company's Scientific Advisory Board as part of the transaction, led the work at the NIH to advance CRB-4001 to clinical testing, including studies in animal models of non-alcoholic fatty liver disease (NAFLD), type 2 diabetes, diet-induced insulin resistance and type 2 diabetic nephropathy.

A Phase 1 study for CRB-4001 is planned in 2019. Following the Phase 1 safety study, Dr. Kunos plans to coordinate a NIH-funded first-in-patient Phase 2 study. Corbus will provide more specific details on the clinical development path of CRB-4001 before the end of 2018.